Associated tags: Immune system, Rintatolimod, COVID-19, Therapy, Viral, Research, AIM, DSM-IV codes, Cancer, Pharmaceutical industry, NYSE, Patient, Disease, Pancreatic cancer, Doctor of Philosophy
Locations: NEW YORK, UNITED STATES, NORTH AMERICA, FLORIDA, NETHERLANDS, EUROPE, OHIO, CHICAGO, ILLINOIS, DELAWARE, AMERICAS, OCALA, FL, US, DC, ERASMUS
OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences.
Key Points:
OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor conferences.
Details for the presentations are as follows:
Patient,
Doctor of Philosophy,
Pembrolizumab,
Ovarian cancer,
AIM,
University,
Conference,
Cisplatin,
MD,
Event,
ME/CFS,
Progression-free survival,
Research,
CGMP,
Webcast OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the first quarter 2024. As previously announced, the Company will host a conference call and webcast today, Thursday, May 16, 2024, at 8:30 AM ET (details below).
Key Points:
- Company to host conference call and webcast today, May 16, at 8:30 AM ET
OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the first quarter 2024.
- “AIM is making fundamental progress across our clinical development programs and continues to be encouraged by Ampligen’s potential.
- As of March 31, 2024, AIM reported cash, cash equivalents and marketable securities of $10.9 million.
- As previously announced, the Company will host a conference call and webcast to discuss the Company’s Q1 2024 operational and financial results today, May 16, 2024 at 8:30 AM ET.
OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET.
Key Points:
- OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET.
- The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer.
- Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call.
- The webcast will be accessible on the Events page of the Investors section of the Company’s website, aimimmuno.com , and will be archived for 90 days following the live event.
OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen ® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
Key Points:
- OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen ® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
- AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies.
- This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success.
- Ampligen has had a series of clinical trial advances in 2024.
OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website.
Key Points:
- OCALA, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website.
- For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, gave an overview of Metastatic Pancreatic Cancer and the ongoing Phase 1b/2 clinical trial combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer (the “DURIPANC Study”).
OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website.
Key Points:
- OCALA, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website.
- For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, gave an overview of Locally Advanced Pancreatic Adenocarcinoma and the unmet need.
FDA,
Albany Medical College,
AIM,
MD,
Myalgia,
International Association,
Chronic fatigue syndrome,
ME/CFS,
CFS,
National Fibromyalgia Association,
Knowledge,
Pharmaceutical industry As a Consulting Medical Officer and an independent contractor, he will help manage the company’s research programs related to ME/CFS and Long COVID, including the development of protocols and new clinical trials.
Key Points:
- As a Consulting Medical Officer and an independent contractor, he will help manage the company’s research programs related to ME/CFS and Long COVID, including the development of protocols and new clinical trials.
- I am devoted to doing whatever I can to get Ampligen FDA-approved and available for commercial use.”
Dr. Lapp is a graduate of Albany Medical College.
- AIM Chief Executive Officer Thomas K. Equels states: “Having worked with Dr. Lapp for many years, I’m continually impressed by his knowledge, confidence and experience.
- He is one of the foremost experts in his field and we are extremely grateful that he is joining the AIM team.”
OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website.
Key Points:
- OCALA, Fla., April 11, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website.
- For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, discussed the Company’s recent news release regarding top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a powerful synergistic effect that could be far more effective than pembrolizumab alone as a therapy for the disease.
Retrieved on:
Wednesday, April 10, 2024
PFS,
University,
Epithelium,
UPMC Magee-Womens Hospital,
Pancreatic cancer,
Triple-negative breast cancer,
Colorectal cancer,
Research,
Cisplatin,
AIM,
MD,
Peritoneum,
Gynecologic Oncology (journal),
UPMC,
Gynaecology,
Disease,
Liver,
Patient,
CXCL10,
CXCL11,
Reproductive Sciences,
Progression-free survival,
Data analysis,
Neoplasm,
Biomarker,
CXCL9,
Cancer,
RNA,
Ovarian cancer,
Medical imaging See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .
Key Points:
- See further details on the study “Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer” at ClinicalTrials.gov: NCT03734692 .
- Additionally, the immunological signature supporting this synergistic enhancement has been seen in other clinical trials, including with pancreatic cancer ( 1 , 2 ) metastatic triple-negative breast cancer and colorectal cancer metastatic to the liver .
- Ampligen is a dsRNA product candidate that acts via the TLR-3 receptor present on several immune cells, epithelial cells and most solid tumors.
- Additionally, Keynote-100’s median PFS was 2.1 months, or significantly less than that seen in the ongoing Ampligen study.
Research,
Conference,
Rintatolimod,
Webcast,
Cancer,
Doctor of Philosophy,
Investment,
Event,
Patent,
Fatigue,
AIM,
Cryptocurrency OCALA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the full year 2023 and provided a business update. As previously announced, the Company will host a conference call and webcast today, Tuesday, April 2, 2024, at 8:30 AM ET (details below).
Key Points:
- Company to host conference call and webcast today, April 2nd at 8:30 AM ET
OCALA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the full year 2023 and provided a business update.
- As previously announced, the Company will host a conference call and webcast today, Tuesday, April 2, 2024, at 8:30 AM ET (details below).
- “AIM reported positive data across many fronts in 2023 and the first quarter of 2024.
- Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call.
